A prospective strategy to restore the tissue damage in malaria infection: Approach with chitosan-trypolyphosphate conjugated nanochloroquine in Swiss mice

Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine

The chloroquine family of antimalarials has a long history of use, spanning many decades. Despite this extensive clinical experience, novel applications, including use in autoimmune disorders, infectious disease, and cancer, have only recently been identified. While short term use of chloroquine or hydroxychloroquine is safe at traditional therapeutic doses in patients without predisposing conditions, administration of higher doses and for longer durations are associated with toxicity, including retinotoxicity. Additional liabilities of these medications include pharmacokinetic profiles that require extended dosing to achieve therapeutic tissue concentrations. To improve chloroquine therapy, researchers have turned toward nanomedicine reformulation of chloroquine and hydroxychloroquine to increase exposure of target tissues relative to off-target tissues, thereby improving the therapeutic index. This review highlights these reformulation efforts to date, identifying issues in experimental designs leading to ambiguity regarding the nanoformulation improvements and lack of thorough pharmacokinetics and safety evaluation. Gaps in our current understanding of these formulations, as well as recommendations for future formulation efforts, are presented.

Effects of Silver Nanoparticle from Dicoma anomala Sond. Root Extract on MCF-7 Cancer Cell Line and NF54 Parasite Strain: an In Vitro Study

Biogenic silver nanoparticles (AgNPs) continue captivating researchers in biomedicine field of research. Dicoma anomala Sond. plant, locally known as hloenya, hlonya, maagbossie, inyongwana, is widely recommended by South African traditional health practitioners (THPs) to treat against different health issues. The antiplasmodial effects of novel sesquiterpene molecules (C₃₀H₃₆O₇; MW: 509.25) isolated from D. anomala Sond. have been reported by us (Patent US 8,586,112 B2). The aim of the study was to determine the anticancer activity of AgNPs synthesized using D. anomala plant root extract and the antiparasitic potency of AgNP-conjugated sesquiterpene. Nanoparticles have been characterized using different methods. Anticancer activity of AgNPs was evaluated against the MCF-7. This study also revealed that the AgNP-conjugated sesquiterpene has shown better antiparasitic activity against Plasmodium falciparum NF54 strain. One-pot synthesized AgNPs using Dicoma anomala Sond. root extract caused oxidative damage in breast cancer cells. These findings indicate the need for more in-depth research in the use of the AgNPs and sesquiterpene for development into potential leads as an antimalarial candidates and to improve the bioavailability of these sesquiterpenes.

A new effective antiplasmodial compound: Nanoformulated pyrimethamine

OBJECTIVES

The aim of this study was to evaluate the efficacy of pyrimethamine-loaded poloxamer 407 nanomicelles on Plasmodium berghei strain NICD in vivo.

METHODS

Pyrimethamine-loaded nanomicelles were prepared and their zeta potential, particle size and polydispersity index were measured. For antiplasmodial assessment, 54 mice were randomly divided into six groups. Four groups were infected intraperitoneally with P. berghei, whereas the two remaining groups did not receive the parasite (negative controls). Three of the P. berghei-infected groups received treatment with either pyrimethamine-loaded nanomicelles (2 mg/kg), pyrimethamine (2 mg/kg) or empty nanomicelles (2 mg/kg); the fourth group remained untreated (positive control). The parasitaemia rate, survival rate and histopathological changes in the liver, spleen and kidneys were examined and were compared with the negative and positive control groups.

RESULTS

The mean parasitaemia rate differed significantly between the nanoformulated pyrimethamine group and each of the other groups (P<0.05). Moreover, the survival rate of mice in the nanoformulated pyrimethamine group (7/9; 78%) was significantly higher compared with each of the other groups (P<0.01). The main histopathological changes, including hepatic necrosis in the liver, lymphoid hypoplasia in the spleen, and tubular nephrosis and perivascular and interstitial lymphocytic infiltration in the kidneys, were considerably lower in the nanoformulated pyrimethamine group than in the pyrimethamine and positive control groups.

CONCLUSION

Pyrimethamine-loaded nanomicelles showed potent antimalarial activity and can be considered as a potential candidate for further examination of their suitability as an antimalarial drug.